The six different kits are designed for the rapid, quantitative measure of either IgG or IgM antibodies in a range of preclinical models.
The new assay kits are the first anti-KLH ELISAs leveraging the Stellar KLH protein, the company said.
KLH can be used to assess both humoral and cellular immune responses.
Stellar Biotechnologies CEO and president Frank Oakes said: "Our goal was to apply Stellar KLH™ technology to improve the predictive value of pharmaceutical immunotoxicology testing using higher quality, standardized products – both KLH protein and assays – not available to researchers before."